Clinical Trials Browser

Interventional × lorvotuzumab mertansine × Clear all

NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Phase 2 Completed

62 enrolled 15 charts

CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

Phase 2 Completed

9 enrolled 7 charts

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00346385 2015-03-26

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

97 enrolled

DermatologicGynecologicThoracic

Ovarian Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

Phase 1 Completed

50 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00346255 2013-04-23

IMGN901

Phase 1 Completed

37 enrolled

Plasma cell

Multiple Myeloma

NCT00065429 2012-07-18

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Phase 1/2 Completed

64 enrolled 13 charts

Thoracic

Small Cell Lung Carcinoma